Clinical trials: Locally Advanced Colorectal Cancer
Colonic Neoplasms, Chemotherapy Effect
The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
Colon cancer is one of the most lethal malignancies, and colorectal cancer ranks the fifth leading cause of tumor-related mortality in China. FOLFOX is the recommended adjuvant/ neoadjuvant treatment for advanced colon cancer.
- Trial name
- JSFOL (NCT03985891)
- Testing
- Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
Clinical Complete Response Rate With Negative MRD
The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial.
This study is a single arm, single center, phase II, prospective clinical study aimed at exploring the effectiveness and safety of watch and wait strategy guided by dynamic minimal disease residual (MRD) monitoring to achieve…
- Trial name
- WINDOW (NCT06477991)
- Testing
- Tireilizumab（PD-1 inhibitor）
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Yunnan Cancer Hospital
Rectal Cancer
Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
This trial compares induction treatment with FOLFOX with or without aflibercept in a high risk population selected by MRI, prior to receiving standard chemoradiation (capecitabine combined with 50.4 Gy in 28 days) and surgery, in…
- Trial name
- RIA (NCT02340949)
- Testing
- Aflibercept, 5-Fluoruracil, Oxaliplatin
- Volunteers
- 180 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Rectal Adenocarcinoma
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal cancer.
- Trial name
- NCT02688712
- Testing
- LY2157299, Capecitabine, Fluorouracil
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Providence Health & Services
Non-Metastatic Adenocarcinoma of the Rectum
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
Background: The investigational anti-cancer drug Selumetinib (AZD6244) prevents a protein found in rectal cancer from working properly, which may slow tumor growth and allow radiation and chemotherapy treatments to destroy more…
- Trial name
- NCT01134601
- Testing
- Radiation Therapy, Capecitabine, AZD6244
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
This phase I trial investigates how well short-course radiation therapy followed by combination chemotherapy works in treating patients with stage II-III rectal cancer.
- Conditions
- Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8
- Trial name
- NCT04703101
- Testing
- Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Rectal Cancer
Ultra-fractionated Radiotherapy for Rectal Cancer
The rationale of this clinical trial is to assess the feasibility of selective non-operative management for locally advanced rectal cancer using dose-escalated ultra-fractionated short course radiation therapy interdigitated with…
- Trial name
- NCT04677413
- Testing
- Ultrafractionated radiotherapy for rectal cancer
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Texas Southwestern Medical Center
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Colon Cancer
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer
A. Background and purpose: Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for unresectable locally advanced colon cancer: an open, multi-centered, randomize controlled phase 3 trial.
- Trial name
- NCT03970694
- Testing
- Radiotherapy, oxaliplatin+capecitabine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Colorectal Cancer
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors
- Conditions
- Solid Tumor, Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07589205
- Testing
- Drug: IBI3028
- Where
- China
- Volunteers
- 493 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Colorectal Cancer
Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer
The scope of the trial is to determine the preference of patients, after randomization and cross-over, for one of the two treatments. Another objective of the trial is to assess and compare the safety of each treatment.
- Trial name
- COLOCROSS (NCT00905047)
- Testing
- XELODA, TEGAFUR URACIL - FOLINIC ACID
- Where
- 13 sites in France
- Volunteers
- 89 people
- Sponsor
- Centre Oscar Lambret
Locally Advanced Unresectable or Stage IV Colorectal Cancer
Stage IV Colorectal CA ALIMTA
Phase I: The primary objective of the Phase 1 portion of this study is to determine the Maximum tolerated dose and the recommended Phase 2 dose of ALIMTA plus oxaliplatin when given with folate and vitamin B-12 supplementation in…
- Trial name
- NCT00166465
- Testing
- ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
RATIONALE: ISIS 2503 may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have metastatic and/or…
- Trial name
- NCT00004193
- Testing
- ISIS 2503
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Rectal Cancer
Computer Navigation-assisted Surgery for Locally Advanced and Recurrent Rectal Cancer
The aim of this study is to investigate feasibility of computer navigation-assisted surgery in particularly difficult cases of locally advanced (LARC) and recurrent (LRRC) rectal cancer where the standard surgical strategy is…
- Trial name
- NAVI-LARRC (NCT04512937)
- Testing
- Computer-assisted navigation surgery
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Rectal Cancer
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial evaluates whether online adaptive radiotherapy (ART) with a sequential boost to both the primary rectal tumor and clinically involved lymph nodes improves pathologic…
- Trial name
- NCT06246344
- Testing
- Online Adaptive Radiotherapy With Sequential Boost, Conventional Non-Adaptive IMRT, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shandong Cancer Hospital and Institute
Rectal Cancer
Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- EXCITE (NCT00972881)
- Testing
- cetuximab, capecitabine, irinotecan hydrochloride
- Where
- 5 sites in United Kingdom
- Volunteers
- 82 people
- Sponsor
- University College, London
Rectal Cancer
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer
The goal of this clinical trial is to learn if neoadjuvant Fruquintinib and Tislelizumab combined with mCapeOX works to treat mid-high pMMR/MSS locally advanced rectal cancer patients compared with CapeOX.
- Trial name
- PKUCH-R09 (NCT06443671)
- Testing
- CapeOX, Fruquintinib and Tislelizumab combined with mCapeOX
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Cancer
Radiomics-based Artificial Intelligence System to Predict Neoadjuvant Treatment Response in Rectal Cancer
In this study, investigators utilize a radiomics prediction model to predict the tumor response to neoadjuvant chemoradiotherapy (nCRT) before the nCRT is administered for patients with locally advanced rectal cancer (LARC).
- Trial name
- MRAI-pCR (NCT04273477)
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer
Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462501
- Testing
- bevacizumab, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Cancer
Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer
The primary objective was to improve adjuvant 5-FU chemoradiotherapy in resectable rectal cancer. The investigators hypothesis was that modulation of 5-FU by addition of either FA or INF-alpha may increase overall survival.
- Trial name
- FOGT1 (NCT01060501)
- Testing
- Folinic Acid, interferon-alpha
- Where
- Germany
- Volunteers
- 796 people
- Sponsor
- University of Ulm